ALSO NOTED: Glaxo wins approval for Hycamtin; Affymax forecasts share price;The best (and worst) biotech stocks of 2006; and mu

> President Bush has signed a new law that expands the powers of federal authorities targeting the activities of animal rights groups. Report

> GlaxoSmithKline has won EMEA approval to market Hycamtin, a combinatorial therapy for cervical cancer. Report

> Affymax has forecast a share price of $22 to $24 a share on the 3.5 million shares it plans to sell in its IPO. Report

> Analysts say that Allos Therapeutics is likely to release positive data for two major cancer trials in December. Report

> Eli Lilly will close its Mont St. Guibert operation and take a charge of $100 million to $110 million. Report

> Talecris Biotherapeutics has set up its European headquarters in Frankfurt, Germany. Release

> Researchers have used RU-486 to ward off tumors in mice bred with a gene that promotes breast cancer. Release

> Chutes & Ladders: Amgen has appointed Yuji Orihara president and representative director of Amgen in Japan. Release

> Dutch biotech Crucell has won contracts worth a collective $230 million for two of its vaccine. Report

> New research appearing in the Journal of Biology shows that even low doses of chemotherapy are killing brain cells and cancer drugs are more malignant to healthy cells than diseased cells. Report

> According to a newly-issued report from PriceWaterhouseCoopers predicts the top 7 trends for the healthcare history in 2007. Report

> The best (and worst) biotech stocks of 2006. Report

And Finally…The Clinton Foundation has announced a new deal that will significantly cut the cost of AIDS drugs for children. Article